Background: Urinary tract infection (UTI) has become the most frequent bacterial infections worldwide. It is well established that Escherichia coli is the predominant cause of UTI. The aim of our study was to evaluate the rates of resistance to fluroquinolone and third generation cephalosporin among the patients with UTI due to E.Coli and to assess the potential correlation between both trends. Methods: The study was a cross sectional observational study conducted at the Department of Pharmacology and Therapeutics in collaboration with Department of Microbiology of Sylhet Women’s Medical College and Hospital from 1st July 2019 to 30th June 2020. Results: A total of 246 urine samples were collected from patients with UTI followed by isolation and identification of E.coli strains. Antibiotic sensitivity and resistance analysis was performed by the disc diffusion method employing multiple antibiotic discs. The sensitivity was monitored by zone of inhibition around the disc. Overall rates of resistance to fluroquinolone and third generation cephalosporin were 70.31% and 65.10% respectively. The rates of co-resistance to both fluroquinolone and third generation cephalosporin was 53.13%. Conclusion: Our study suggests that fluroquinolone should be reserved and third generation cephalosporin should be used with caution among patients with E.coli.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.